Wockhardt jumps 4% on USFDA nod for new injection

NEW DELHI: Shares of pharmaceutical firm Wockhardt jumped nearly 4 per cent in early trade on Thursday after it received the USFDA nod for Decitabine injection.

The company on Wednesday said it had received approval from the US health regulator for its 50 mg Decitabine injection which is used to treat certain forms of cancer.

As per PTI, Decitabine is used to treat Myelodysplastic syndromes (MDS) -- a group of cancers in which immature blood cells in the bone marrow do not mature and, therefore, do not become healthy blood cells. Wockhardt will launch this product in the US within a short period of time.


Shares of the company closed 1.14 per cent up at Rs 447.10 apiece on BSE.